Literature DB >> 18405488

[Acute intermittent porphyria and chronic transaminase elevation].

M Yolanda Raigal Martín1, José Luis Lledó Navarro, José María Raigal Martín, Eva Muriel Patino, Encarnación Pérez Pérez, Miriam Moreno Prat.   

Abstract

Acute intermittent porphyria is an autosomal dominant inherited disorder resulting from a deficiency of porphobilinogen deaminase activity, the third enzyme in the heme biosynthesis pathway. This disease is uncommon, although the prevalence is higher in asymptomatic heterozygotic carriers; however, this prevalence is difficult to establish because of the absence of symptoms. Although acute intermittent porphyria is a multisystemic disease, its most common form of presentation is abdominal pain and neurological or mental symptoms, which can sometimes be due to precipitating factors such as reduced energy intake, smoking, alcohol, some drugs, and stress. Diagnosis can be made by testing urinary porphobilinogen levels, with subsequent measurement of enzyme activity and DNA testing. Treatment is based on prevention of porphyria attacks by avoiding precipitating factors and early administration of intravenous glucose or hemin therapy. We present the case of a patient diagnosed with acute intermittent porphyria based on study of chronic mild alanine aminotransferase (ALT) elevation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18405488     DOI: 10.1157/13117900

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  2 in total

Review 1.  Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria.

Authors:  Enrique Esteve-Valverde; Alfonso Tapiz-Reula; Domingo Ruiz; Jaume Alijotas-Reig
Journal:  Rheumatol Int       Date:  2019-12-21       Impact factor: 2.631

2.  Chronic elevation of liver enzymes in acute intermittent porphyria initially misdiagnosed as autoimmune hepatitis.

Authors:  A González Estrada; S García-Morillo; L Gómez Morales; P Stiefel García-Junco
Journal:  Int J Hepatol       Date:  2011-01-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.